Published in Pain on July 06, 2010
Selective corticospinal tract injury in the rat induces primary afferent fiber sprouting in the spinal cord and hyperreflexia. J Neurosci (2012) 1.09
Elevated IL-1β and IL-6 levels in lumbar herniated discs in patients with sciatic pain. Eur Spine J (2012) 1.08
Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. PLoS One (2011) 1.05
Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated BV-2 microglia. PLoS One (2014) 0.81
Current gene therapy using viral vectors for chronic pain. Mol Pain (2015) 0.79
Neuropeptides and Microglial Activation in Inflammation, Pain, and Neurodegenerative Diseases. Mediators Inflamm (2017) 0.79
A new rat model of bone cancer pain produced by rat breast cancer cells implantation of the shaft of femur at the third trochanter level. Cancer Biol Ther (2012) 0.77
Substance P spinal signaling induces glial activation and nociceptive sensitization after fracture. Neuroscience (2015) 0.76
Full-length membrane-bound tumor necrosis factor-α acts through tumor necrosis factor receptor 2 to modify phenotype of sensory neurons. Pain (2013) 0.76
Dynamic weight bearing is an efficient and predictable method for evaluation of arthritic nociception and its pathophysiological mechanisms in mice. Sci Rep (2015) 0.76
Close encounters of the third kind: evidence for contact with TNF-alpha. Pain (2010) 0.75
Crosstalk between JNK and NF-κB in the KDO2-mediated production of TNFα in HAPI cells. Cell Mol Neurobiol (2012) 0.75
The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell (1995) 5.08
Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci (2009) 5.00
Microglia as a source and target of cytokines. Glia (2002) 4.48
Role of the immune system in chronic pain. Nat Rev Neurosci (2005) 4.10
Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther (2003) 3.69
Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain (2005) 3.34
The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology (2005) 3.18
Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci (2003) 2.89
Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev (2002) 2.75
JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci (2009) 2.64
Can we conquer pain? Nat Neurosci (2002) 2.56
Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha. J Neurosci (2006) 2.47
Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist (2004) 2.40
Spontaneous pain, both neuropathic and inflammatory, is related to frequency of spontaneous firing in intact C-fiber nociceptors. J Neurosci (2006) 2.32
The molecular dynamics of pain control. Nat Rev Neurosci (2001) 2.21
Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines. J Neurosci (2001) 2.07
TNF-alpha and TNF-alpha receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies in murine DRG and spinal cord. Spine (Phila Pa 1976) (2004) 1.93
Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience (2001) 1.91
Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation. J Neurosci (2003) 1.88
Glia: novel counter-regulators of opioid analgesia. Trends Neurosci (2005) 1.86
Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. J Pharmacol Exp Ther (2001) 1.81
Glial activation and pathological pain. Neurochem Int (2004) 1.80
In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci (2005) 1.72
Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol (1998) 1.53
Characterization of a novel brain-derived microglial cell line isolated from neonatal rat brain. Glia (2001) 1.51
The role of tumor necrosis factor-alpha in the neuropathic pain induced by Lumbar 5 ventral root transection in rat. Pain (2006) 1.49
Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res (1996) 1.48
Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in rats. Exp Neurol (2008) 1.46
Spinal glial activation and cytokine expression after lumbar root injury in the rat. Spine (Phila Pa 1976) (2000) 1.45
Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. Ann Neurol (2006) 1.43
Temporal expression of cytokines and their receptors mRNAs in a neuropathic pain model. Neuroreport (2004) 1.40
Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev (2004) 1.39
Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther (2007) 1.37
Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci (2004) 1.36
Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38. Neurosci Lett (2005) 1.35
Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha. J Immunol (1997) 1.25
Epineurial application of TNF elicits an acute mechanical hyperalgesia in the awake rat. J Peripher Nerv Syst (2000) 1.24
HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microglia. Gene Ther (2007) 1.22
Spinal cord substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. Neuroscience (1996) 1.22
The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw (2000) 1.21
Increase of interleukin-6 mRNA in the spinal cord following peripheral nerve injury in the rat: potential role of IL-6 in neuropathic pain. Brain Res Mol Brain Res (1998) 1.21
Increased sensitivity of sensory neurons to tumor necrosis factor alpha in rats with chronic compression of the lumbar ganglia. J Neurophysiol (2002) 1.19
Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain. Brain Res (2000) 1.19
Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy. Brain Res (1997) 1.19
Selective stimulation of either tumor necrosis factor receptor differentially induces pain behavior in vivo and ectopic activity in sensory neurons in vitro. Neuroscience (2008) 1.11
Distinct neurochemical features of acute and persistent pain. Proc Natl Acad Sci U S A (1999) 1.08
Acute topical application of tumor necrosis factor alpha evokes protein kinase A-dependent responses in rat sensory neurons. J Neurophysiol (2002) 1.08
Transgenic expression of TNF by astrocytes increases mechanical allodynia in a mouse neuropathy model. Neuroreport (2000) 1.06
Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells. J Immunol (2007) 1.03
Up-regulation of tumor necrosis factor-alpha in spinal cord contributes to vincristine-induced mechanical allodynia in mice. Neurosci Lett (2008) 0.95
Alarm or curse? The pain of neuroinflammation. Brain Res Rev (2008) 0.83
Lumbar nerve root injury induces central nervous system neuroimmune activation and neuroinflammation in the rat: relationship to painful radiculopathy. Spine (Phila Pa 1976) (2002) 0.83
Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum (2003) 3.39
In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3. Ann Neurol (2002) 1.74
Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther (2004) 1.56
Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol (2005) 1.47
Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. Ann Neurol (2006) 1.43
Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol (2002) 1.40
HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol Pain (2006) 1.32
Gene therapy for pain: results of a phase I clinical trial. Ann Neurol (2011) 1.31
Progress in gene therapy for neurological disorders. Nat Rev Neurol (2013) 1.22
Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annu Rev Microbiol (2004) 1.21
Herpes vector-mediated gene transfer in the treatment of chronic pain. Mol Ther (2008) 1.17
IL-10 promotes neuronal survival following spinal cord injury. Exp Neurol (2009) 1.16
Glial TNFα in the spinal cord regulates neuropathic pain induced by HIV gp120 application in rats. Mol Pain (2011) 1.15
Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes (2002) 1.14
Interleukin-10 provides direct trophic support to neurons. J Neurochem (2009) 1.14
Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain (2007) 1.13
Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci (2008) 1.13
Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem (2010) 1.11
HSV-mediated gene transfer of the glial cell-derived neurotrophic factor provides an antiallodynic effect on neuropathic pain. Mol Ther (2003) 1.07
Effects of transgene-mediated endomorphin-2 in inflammatory pain. Eur J Pain (2008) 1.06
Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain (2004) 1.04
Applications of gene therapy to the treatment of chronic pain. Curr Gene Ther (2008) 1.03
The relationship of herpes simplex virus latency associated transcript expression to genome copy number: a quantitative study using laser capture microdissection. J Neurovirol (2002) 1.01
Soluble Nogo receptor down-regulates expression of neuronal Nogo-A to enhance axonal regeneration. J Biol Chem (2009) 1.00
Neuroprotective effect of herpes simplex virus-mediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion neurons. Brain (2009) 0.97
Long-term neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system. Mol Ther (2005) 0.96
Release of GABA from sensory neurons transduced with a GAD67-expressing vector occurs by non-vesicular mechanisms. Brain Res (2006) 0.94
Vector-mediated release of GABA attenuates pain-related behaviors and reduces Na(V)1.7 in DRG neurons. Eur J Pain (2011) 0.93
Gene therapy directed at the neuroimmune component of chronic pain with particular attention to the role of TNF alpha. Neurosci Lett (2008) 0.93
Neuronal Nogo-A regulates glutamate receptor subunit expression in hippocampal neurons. J Neurochem (2011) 0.93
Gene delivery using herpes simplex virus vectors. DNA Cell Biol (2002) 0.92
Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo. Mol Ther (2004) 0.91
Development of replication-defective herpes simplex virus vectors. Methods Mol Med (2002) 0.90
Gene therapy: novel treatments for polyneuropathy and chronic pain. Curr Neurol Neurosci Rep (2004) 0.90
Prevention of diabetic neuropathy by regulatable expression of HSV-mediated erythropoietin. Mol Ther (2010) 0.90
Protective effect of HSV-mediated gene transfer of nerve growth factor in pyridoxine neuropathy demonstrates functional activity of trkA receptors in large sensory neurons of adult animals. Eur J Neurosci (2003) 0.89
BEND6 is a nuclear antagonist of Notch signaling during self-renewal of neural stem cells. Development (2013) 0.88
HSV-mediated delivery of erythropoietin restores dopaminergic function in MPTP-treated mice. Mol Ther (2006) 0.88
The role of TNFα in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats. Neuropsychopharmacology (2010) 0.87
Development of a peptide-targeted, myocardial ischemia-homing, mesenchymal stem cell. J Drug Target (2011) 0.87
Herpes simplex virus vector-mediated expression of interleukin-10 reduces below-level central neuropathic pain after spinal cord injury. Neurorehabil Neural Repair (2012) 0.87
A clinical trial of gene therapy for chronic pain. Pain Med (2009) 0.86
Targeted drug delivery to the peripheral nervous system using gene therapy. Neurosci Lett (2012) 0.86
Transgene-mediated enkephalin expression attenuates signs of naloxone-precipitated morphine withdrawal in rats with neuropathic pain. Behav Brain Res (2008) 0.86
Gene therapy for the treatment of sensory neuropathy. Expert Opin Biol Ther (2006) 0.85
Replication-defective genomic HSV gene therapy vectors: design, production and CNS applications. Curr Opin Mol Ther (2005) 0.85
Axon sorting within the spinal cord marginal zone via Robo-mediated inhibition of N-cadherin controls spinocerebellar tract formation. J Neurosci (2012) 0.84
Use of HSV vectors to modify the nervous system. Curr Opin Drug Discov Devel (2002) 0.84
Therapeutic gene transfer to the nervous system using viral vectors. J Neurovirol (2003) 0.84
Reduction of voltage gated sodium channel protein in DRG by vector mediated miRNA reduces pain in rats with painful diabetic neuropathy. Mol Pain (2012) 0.84
Rho GTPase regulation of α-synuclein and VMAT2: implications for pathogenesis of Parkinson's disease. Mol Cell Neurosci (2011) 0.83
Vector-mediated gene transfer to express inhibitory neurotransmitters in dorsal root ganglion reduces pain in a rodent model of lumbar radiculopathy. Spine (Phila Pa 1976) (2006) 0.83
Gene therapy for chronic pain. Curr Opin Mol Ther (2003) 0.82
HSV vectors for gene therapy of chronic pain. Curr Opin Mol Ther (2008) 0.82
Bcl-2 and GDNF delivered by HSV-mediated gene transfer after spinal root avulsion provide a synergistic effect. J Neurotrauma (2002) 0.82
HSV-mediated transfer of artemin overcomes myelin inhibition to improve outcome after spinal cord injury. Mol Ther (2009) 0.82